| Document |
Document Title |
|
WO/2022/152140A1 |
Bridged heterocyclyl-substituted pyrimidine compounds, a preparation method and medical use thereof. The compounds or pharmaceutical compositions comprising same can be used as JAK1 and TYK2 kinase inhibitors for treating JAK1 and TYK2 k...
|
|
WO/2022/153962A1 |
The problem to be solved by the present invention is to provide: a compound useful as a hole transport material for photoelectric conversion elements whereby electric current can be efficiently taken out; and a photoelectric conversion e...
|
|
WO/2022/148879A1 |
The present disclosure relates to compounds of formula (I) comprising a heteroaryl, such as derivatives of quinazolines, which can act as modulators of ACKR3. The present disclosure also relates to the use of these compounds as a drug.
|
|
WO/2022/148243A1 |
Disclosed are a pyrimidine small-molecule compound and an application thereof. The pyrimidine small-molecule compound has efficient inhibitory activity towards PDGFRα and PDGFRβ kinases, but has relatively weak inhibitory activity towa...
|
|
WO/2022/147620A1 |
The present application relates to compounds of Formula (I) or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs...
|
|
WO/2022/038365A9 |
The invention relates to compounds of formula (I) and to their use in treating or preventing an inflammatory disease or a disease associated with an undesirable immune response: wherein R, R1, R2 and RB are as defined herein.
|
|
WO/2022/149618A1 |
The present invention provides a method for producing a compound having alkylated acidic functional groups. The method includes alkylating acidic functional groups by reacting, in a mixture containing a compound having two or more types ...
|
|
WO/2022/148317A1 |
A 2-aminopyrimidine compound having a structure represented by formula (I), or a pharmaceutically acceptable salt thereof, an isotope derivative thereof, a solvate thereof, or a stereoisomer thereof, a geometric isomer thereof, a tautome...
|
|
WO/2022/143771A1 |
Provided are an RORγt modulator, and a preparation method therefor and an application thereof. The RORγt modulator is selected from a compound represented by formula I, and a pharmaceutically acceptable salt, solvate, solvate of the ph...
|
|
WO/2022/139304A1 |
The present invention relates to a novel quinazoline derivative compound that serves as an SOS1 inhibitor, and a use thereof, and more specifically to: a novel quinazoline derivative compound having inhibitory activity against SOS1 bindi...
|
|
WO/2022/140456A1 |
This disclosure is in the field of medicinal chemistry, and relates to a new class of small-molecules having the Formula I, or a pharmaceutically acceptable salt or solvate thereof, or an enantiomer, a mixture of enantiomers, a mixture o...
|
|
WO/2022/134488A1 |
Provided is a related substance 4,4'-(2-methylpropane-1,3-diyl)bis(2-(chloromethyl)quinazoli
ne) of the linagliptin intermediate 2-chloromethyl-4-methylquinazoline. Further provided are a method for synthesizing the related substance (im...
|
|
WO/2022/133551A1 |
The present application is directed towards compounds, pharmaceutically acceptable salts or prodrugs thereof, which are inhibitors of Histone Deacetylase (HDAC) binding or function. The compounds especially may have some selectivity for ...
|
|
WO/2022/140554A1 |
The present invention relates to bifunctional compounds, compositions, and methods for treating diseases or conditions by modulating (e.g., reducing) the level or activity of at least one of PIP4K2A, PIP4K2B, and PIP4K2C.
|
|
WO/2022/135534A1 |
A novel substituted nitrogen-containing bicyclic compound and a pharmaceutical composition containing the compound, capable of being used as chymase inhibitors. Also provided are methods for preparing the compound and pharmaceutical comp...
|
|
WO/2022/138387A1 |
A composition comprising a resin (A) and a compound (B) which comprises a cation and an anion having a partial structure represented by formula (I). [In formula (I), ring W1 represents an optionally substituted ring structure, and ring W...
|
|
WO/2022/131887A1 |
The present invention relates to a novel compound with excellent carrier transport ability, light-emitting ability, and thermal stability, and an organic electroluminescent device that includes the compound in at least one organic materi...
|
|
WO/2022/127518A1 |
Disclosed by the present application are a nitrogen-containing organic compound and an electronic component and electronic apparatus using same; the nitrogen-containing organic compound has an adamantyl-substituted nitrogen-containing he...
|
|
WO/2022/127923A1 |
The present invention relates to a benzene ring compound and a use thereof. In particular, provided is a compound as shown in formula I, or an optical isomer thereof or a racemate thereof, or a solvate thereof, or a pharmaceutically acce...
|
|
WO/2022/129914A1 |
The present invention relates to compounds of Formula (I), in particular of Formulae (II) to (IV), that are inhibitors of c-ABL. The invention also relates to pharmaceutical compositions comprising those compounds, and to their use in th...
|
|
WO/2022/131135A1 |
The purpose of one mode of the present disclosure is to provide: a novel pyrimidine compound for forming an organic electroluminescent element that exerts high electric current efficiency; and an organic electroluminescent element materi...
|
|
WO/2022/133097A1 |
The disclosure provides processes for preparing spiro derivatives, in particular (2R,5S)-7-methyl-2-[4-methyl-6-[4-(trifluoromethyl)-phenyl]p
yrimidin-2-yl]-1,7- diazaspiro[4.4]nonan-6-one, as well as intermediates for use in said proces...
|
|
WO/2022/129933A1 |
Disclosed are compounds of the formula (I) and pharmaceutically acceptable salts thereof: (I) wherein Ring A, Ring B, Ring C, R1, R2, R3, R4, R5, L, m, n, and p are as defined herein. The compounds are modulators of G-protein coupled rec...
|
|
WO/2022/129259A1 |
The invention relates to a compound of formula (I) wherein A, L, R1, R2, R3 and R4 are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.
|
|
WO/2022/129047A2 |
The present invention is directed to novel modulators of the NMDA receptor. Separate aspects of the inventions are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat neurological disorder...
|
|
WO/2022/129041A1 |
The present invention is directed to novel prodrugs of modulators of the NMDA receptor. Separate aspects of the inventions are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat neurologi...
|
|
WO/2022/127909A1 |
A pyrimidine carboxamide compound as shown in formula I, or a tautomer, mesomer, racemate, enantiomer and diastereomer thereof, or a mixture form thereof, or a pharmaceutically acceptable salt thereof, which can be used as a Vanin enzyme...
|
|
WO/2022/132676A1 |
The present invention relates to oral dosage forms comprising letermovir and, in particular, to compressed mini-tablets comprising letermovir. The invention also relates to methods of using the oral dosage forms for the treatment, preven...
|
|
WO/2022/129909A1 |
The present invention relates to a group of novel compounds, methods for their manufacture and the use of these compounds as research tools and as pharmaceuticals. The novel compounds are analogues of cannabidiol (CBD). CBD is a non-psyc...
|
|
WO/2022/125613A1 |
Compounds having activity as inhibitors of ENPP1, CdnP, or both are provided herein. Some embodiments provide compounds having one of the following Structures (I) or (II): or a pharmaceutically acceptable salt, tautomer, stereoisomer, or...
|
|
WO/2022/023496A9 |
The present invention relates to functionalized isonitrile compounds, formed by means of multicomponent environmentally friendly reactions, suitable for coupling to functional molecules such as biomolecules, APIs, chromophore and fluorop...
|
|
WO/2022/122773A1 |
The present invention relates to 4-(2-Fluoro-4-methoxy-5-3-(((l- methylcyclobutyl)methyl)carbamoyl)bicyclo[2.2.1]heptan-2-yl)
carbamoyl)phenoxy)-l-methylcyclohexane-l-carboxylic acid derivatives and similar compounds of formula (I) as R...
|
|
WO/2022/125636A1 |
Methods are provided for modulating MRGPRX2 generally, or for treating a MRGPRX2 dependent condition more specifically, by contacting the MRGPRX2 or administering to a subject in need thereof, respectively, an effective amount of a compo...
|
|
WO/2022/124827A1 |
The present invention relates to a novel compound having excellent carrier transport ability, light-emitting ability, and thermal stability, and an organic electroluminescent device having improved characteristics in terms of luminescenc...
|
|
WO/2022/125412A1 |
The present disclosure is directed to tetrahydroquinazoline derivatives of Formula (I) and their use for selectively killing HIV infected GAG-POL expressing cells without concomitant cytotoxicity to HIV naive cells, and for the treatment...
|
|
WO/2022/120136A1 |
Provided herein, in part, are compounds and compositions useful for preparing pralsetinib. Also provided herein are processes for preparing pralsetinib.
|
|
WO/2022/119823A1 |
Positive allosteric modulators (PAMs) of Mas-related G protein-coupled receptor X1 (MRGPRX1) and their use for treating neuropathic pain is disclosed.
|
|
WO/2022/118910A1 |
[Problem] The purpose of the present invention is to provide a compound that has a high refractive index with respect to the wavelength range of 450-750 nm in a capping layer, in order to improve the light extraction efficiency of an org...
|
|
WO/2022/118959A1 |
The problem addressed by the present invention is to provide a compound used in the formation of an optically anisotropic film that excels in a reverse wavelength dispersion property and a heat-and-moisture durability property, a polymer...
|
|
WO/2022/118951A1 |
The present invention addresses the problem of providing: a compound to be used in forming an optically anisotropic film having excellent reverse wavelength dispersion properties; a polymerizable composition; an optically anisotropic fil...
|
|
WO/2022/111621A1 |
Provided herein are novel compounds (e.g., Formula I or II), pharmaceutical compositions, and methods of using related to cyclin dependent kinases (CDKs). The compounds herein are typically CDK2 inhibitors, which can be used for treating...
|
|
WO/2022/111694A1 |
The present invention relates to a quinazolinone compound, a preparation method therefor and an application thereof. The compound has a structure represented by formula (I) or formula (LI), has an excellent HPPD inhibitory effect and a s...
|
|
WO/2022/105792A1 |
Provided are a crystal form D, a crystal form AJ, a crystal form AL, a crystal form AZ, a crystal form AF, a crystal form Z and a crystal form AE of a compound of formula (I), a preparation method therefor and use thereof. The crystal fo...
|
|
WO/2022/105836A1 |
Provided are one or more combination treatments of cancer patients with a compound of formula (I), as described herein, and an allosteric inhibitor or an immune checkpoint molecule.
|
|
WO/2022/105859A1 |
KRAS G12D inhibitors of Formula (I), a composition containing the inhibitor and the use thereof.
|
|
WO/2022/109001A1 |
Described herein are compounds that are inhibitors of GCN2 kinase or PERK kinase, and methods of treating diseases, including diseases associated with GCN2 kinase or PERK kinase, with said compounds.
|
|
WO/2022/100577A1 |
Provide crystal forms of 5-fluoro-1- (4-fluoro-3- (4- (pyrimidin-2-yl) piperazine-1-carbonyl) benzyl) quinazoline-2, 4 (1H, 3H) -dione and preparation method thereof.
|
|
WO/2022/099374A1 |
The present invention relates to a compound of formula (I): or a salt or solvate thereof, combinations comprising same, uses and methods thereof, and kits comprising same.
|
|
WO/2022/103031A1 |
Provided is a triazine or pyrimidine derivative that contributes to a substantial improvement in lifespan of an organic electroluminescent element by effectively absorbing high energy in the UV range from an external light source to mini...
|
|
WO/2022/099442A1 |
The present invention relates to crystalline forms of 5-fluoro-1-(4-fluoro-3-(4-(pyrimidin-2-yl)piperazine-1-carbo
nyl)benzyl)quinazoline-2,4(1H,3H)-dione selected from crystalline forms VIII, I, II, III, V, VI and the like.
|
